Navigation Links
Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
Date:2/17/2011

FRANKLIN, Mass., Feb. 17, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that development of the commercially ready Symphony tCGM System is ahead of schedule.  The company said that the system will be ready for demonstration in the second quarter and it will be used in a clinical trial shortly thereafter, replacing the prototype used in earlier clinical trials.  

Echo said it anticipates that upon completion of the development work no further changes will be made to the Symphony tCGM System, and that the device will be the one used for sale, subject to positive clinical studies and FDA market clearance of the product.  The addressable market for needle-free, continuous wireless glucose monitoring in the hospital critical care setting exceeds $1 billion annually and the global glucose monitoring market exceeds $12 billion annually.

"With the successful completion of our recent financing we now have sufficient capital to accelerate the product development work of our Symphony tCGM System," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are now prepared to complete our final development work and clinical validation.  This next generation Symphony device incorporates substantial improvements beyond the prototype used in earlier studies and we look forward to validating those improvements in clinical testing."  

The Symphony tCGM System incorporates Echo's proprietary Prelude SkinPrep System, with a noninvasive wireless biosensor and a wireless monitor or handheld device for needle-free, continuous monitoring of glucose levels.  

About Echo TherapeuticsEc
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
3. Echo Therapeutics Announces Appointments to Board of Directors
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
6. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
7. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
8. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
9. NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
10. DSM and NKT Therapeutics Sign Contract for Lead Product Development and Manufacture
11. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... /PRNewswire-iReach/ -- Reproductive Medicine Associates of New York ... a nationally and internationally-recognized leader in providing exceptional quality ... pleased to announce a new collaboration with EMD Serono ... recognize the sacrifices made by veterans and their families ... will allow qualifying veterans and the spouses of veterans ...
(Date:7/22/2014)... , July 22, 2014 BioDelivery Sciences ... that its Board of Directors has appointed Charles ... Feinberg as members of the Board.  ... with extensive experience in marketing, sales and other commercial ... Pearl Therapeutics, Inc., a development stage company that was ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ™ ... neuropsychiatric disorders, today announced that enrollment has begun in ... stimulation (eTNS) as adjunctive therapy for the treatment of ... conducted at the Olive View-UCLA Medical Center in ...
Breaking Medicine Technology:Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Va. (PRWEB) July 22, 2014 ... 10, at the Ronald Reagan Building and International ... Forward: Warriors, Military Families and Civilian Communities,” will ... (registration opens at 7:30 a.m.) and cohosted by ... the National Defense Industrial Association (NDIA). USAA is ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 ... deep in the veins of the legs appear no different ... greater risk of bleeding and average hospitalization bills that are ... study finds. The standard treatment for these clots -- ... and compression stockings. The other, more expensive treatment delivers medication ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor Tomas ... Los Angeles with the 2014 E. Donnall Thomas Lecture ... discovery of the iron-regulatory hormone hepcidin and investigation of ... the Nobel Prize Laureate and past Society president E. ... that have represented a paradigm shift or significant discovery ...
(Date:7/22/2014)... electric power morcellation, uterine cancers were present in 27 ... according to a study published by JAMA . ... the uterus is fragmented into smaller pieces, may result ... commercial availability of electric power morcellators for 2 decades, ... time of electric power morcellation (in this study referred ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2
... cancer may also mean surviving pain, according to a study ... of cancer survivors at least two years post diagnosis have ... ahead of print in the American Cancer Society,s journal ... among the growing number of U.S. cancer survivors. ...
... Jan. 13 (HealthDay News) -- This winter will not be a ... to be a more typical flu season, experts say. And ... shot, advice that seniors in particular should heed since the prevalent ... hardest, the experts added. The H1N1 flu virus tended to strike ...
... data from counties across the United States led to the ... risk factor for suicide, according to a provocative study published ... Biology , a peer-reviewed journal published by Mary Ann Liebert, ... Brenner, MD, PhD, and David Cheng, MD, University Hospitals Case ...
... receive more information about the pitfalls of breast cancer screening, ... false-positive results faced serious anxiety and reduced quality of life ... online by BJS, the British Journal of Surgery , ... is abnormal but no cancer is present - had to ...
... COLUMBUS, Ohio New research shows that oncolytic viruses, ... more effective in treating deadly brain tumors if equipped ... The enzyme, called chondroitinase, helps the cancer-killing virus clear ... fill space between cells and impede the virus,s movement ...
... the Kimmel Cancer Center at Jefferson and two other ... protein SIRT1, known for its life-spanning effects in different ... to prostate cancer, prostatic intraepithelial neoplasia (PIN). ... cancer prevention drugs that could not only block prostate ...
Cached Medicine News:Health News:Cancer survivors likely to experience pain at some point in care: U-M study shows 2Health News:Flu Season Looks Normal This Year, Experts Say 2Health News:Women with false-positive mammograms report high anxiety and reduced quality of life 2Health News:Women with false-positive mammograms report high anxiety and reduced quality of life 3Health News:Virus might fight brain tumors better if armed with bacterial enzyme, study shows 2Health News:'Longevity' protein SIRT1 may ward off precursor to prostate cancer 2
... the typical patient, right for the not-so-typical ... you have the ability to address the ... least expect themeven after implant. St. Jude ... to be prepared in almost any situation, ...
... The R4Mplus offers global companies a ... meet RFID compliance initiatives. With die-cast ... variety of connectivity options, and complex ... a super value. Plus, the fully ...
... combines enhanced memory, processing capacity, ... reliable all-metal construction. Proven platform ... print speed make it the ... value reliability, productivity, consistent print ...
... companies a cost-effective and dependable performer ... With die-cast metal construction, centralized printer/encoder ... and complex multi-language font support, the ... the fully integrated RFID reader/encoder supports ...
Medicine Products: